Literature DB >> 11983245

HIV T cell vaccines, the importance of clades.

Andrew McMichael1, Matilu Mwau, Tomás Hanke.   

Abstract

Development of an HIV vaccine presents a formidable challenge. One of the unresolved, yet central issues is the importance of HIV variability. Here we argue that even with the recent focus on the induction of T cell-mediated immunity, HIV vaccines should match the local circulating HIV clades. Whether used alone or in a combination with vaccines eliciting HIV-neutralizing antibodies, efforts must be made to develop a T cell vaccine that stimulates a broad and long-lasting response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983245     DOI: 10.1016/s0264-410x(02)00067-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry.

Authors:  Jason G Williams; Kenneth B Tomer; Catarina E Hioe; Susan Zolla-Pazner; Philip J Norris
Journal:  J Am Soc Mass Spectrom       Date:  2006-07-27       Impact factor: 3.109

2.  High polymorphism rates in well-known T cell epitopes restricted by protective HLA alleles during HIV infection are associated with rapid disease progression in early-infected MSM in China.

Authors:  Chuan He; Xiaoxu Han; Hui Zhang; Fanming Jiang; Minghui An; Bin Zhao; Haibo Ding; Zining Zhang; Tao Dong; Hong Shang
Journal:  Med Microbiol Immunol       Date:  2019-03-08       Impact factor: 3.402

3.  Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes.

Authors:  Jianming Tang; Emmanuel Cormier; Jill Gilmour; Matthew A Price; Heather A Prentice; Wei Song; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

4.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.

Authors:  Eva Van Braeckel; Patricia Bourguignon; Marguerite Koutsoukos; Frédéric Clement; Michel Janssens; Isabelle Carletti; Alix Collard; Marie-Ange Demoitié; Gerald Voss; Geert Leroux-Roels; Lisa McNally
Journal:  Clin Infect Dis       Date:  2011-01-05       Impact factor: 9.079

6.  The antiviral efficacy of HIV-specific CD8⁺ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate.

Authors:  Srinika R F Ranasinghe; Holger B Kramer; Cynthia Wright; Benedikt M Kessler; Katalin di Gleria; Yonghong Zhang; Geraldine M Gillespie; Marie-Eve Blais; Abigail Culshaw; Tica Pichulik; Alison Simmons; Sarah L Rowland-Jones; Andrew J McMichael; Tao Dong
Journal:  PLoS Pathog       Date:  2011-05-12       Impact factor: 6.823

7.  Design and pre-clinical evaluation of a universal HIV-1 vaccine.

Authors:  Sven Létourneau; Eung-Jun Im; Tumelo Mashishi; Choechoe Brereton; Anne Bridgeman; Hongbing Yang; Lucy Dorrell; Tao Dong; Bette Korber; Andrew J McMichael; Tomás Hanke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.